MedTrace Logo

The Effect of Periarticular Multi-Drug Regimen on Pain After Partial Hip Replacement

NCT01112436 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 258

Last updated 2011-06-27

No results posted yet for this study

Summary

This prospective randomized study aims to evaluate the effectiveness of periarticular multi-drug regimen injection on the relief of pain in patients undergoing partial hip replacement.

Total 258 patients will be randomized into one of two groups (groupC or groupI) based on Excel number generation.

Patients in group C will receive no medication intraoperatively, and patients in group I will receive oral oxycodone and celecoxib preoperatively and a periarticular injection of multi-drug regimen during operation.

Visual analogue scale pain scores, fentanyl consumption and the frequency at which patients pushed the button (FPB) of a patient-controlled analgesia system will be recorded at 1, 4, 7 postoperative day.

Conditions

  • Femoral Neck Fracture

Interventions

DRUG

periarticular injection of multidrug regimen

periarticular injection of combination of ropivacaine 15 mg, epinephrine 0.3mg, cefmetazole 1000mg, ketorolac 30mg, morphine HCL 10 mg

DRUG

none of medication preoperatively and intraoperatively

Patients in Group C wil receive none of medication preoperatively and intraoperatively

Sponsors & Collaborators

  • Chung-Ang University Hosptial, Chung-Ang University College of Medicine

    lead OTHER

Principal Investigators

  • Yong Chan Ha, M.D. & Ph.D. · Chung-Ang University Hosptial, Chung-Ang University College of Medicine

  • Hyun Kang, M.D. & Ph.D. · Chung-Ang University Hosptial, Chung-Ang University College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01112436 on ClinicalTrials.gov